{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:14Z","timestamp":1787016974027,"version":"build-2736575974"},"reference-count":16,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,8,15]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>Eluxadoline is a novel medication that was approved in the USA in 2015 for the treatment of diarrhoea-predominant irritable bowel syndrome. Due to its unique mechanism of action as both an opioid agonist and antagonist, it has been placed as a schedule IV controlled substance. Since its approval, there have been several cases of eluxadoline-induced pancreatitis reported in the literature. The majority of patients who presented with eluxadoline-induced pancreatitis were reported to have had a prior cholecystectomy. Due to this, the Food and Drug Administration released a warning in 2017 that eluxadoline should no longer be used in patients who do not have a gall bladder. We present a rare case of an adult man without prior cholecystectomy who presented with severe mid-epigastric pain and was found to have eluxadoline-induced pancreatitis.<\/jats:p>","DOI":"10.1136\/bcr-2019-231185","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T07:39:48Z","timestamp":1567064388000},"page":"e231185","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Eluxadoline-induced pancreatitis occurring in an adult man without a prior cholecystectomy"],"prefix":"10.1136","volume":"12","author":[{"given":"Zainab","family":"Shahid","sequence":"first","affiliation":[{"name":"Lake Erie College of Osteopathic Medicine, Erie, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Packard","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Groff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"2025082709171046000_12.8.e231185.1","first-page":"632","article-title":"Acute pancreatitis","volume":"90","author":"Quinlan","year":"2014","journal-title":"Am Fam Physician"},{"key":"2025082709171046000_12.8.e231185.2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0889-8553(21)00513-6","article-title":"Hyperlipidemic pancreatitis","volume":"19","author":"Toskes","year":"1990","journal-title":"Gastroenterol Clin North Am"},{"key":"2025082709171046000_12.8.e231185.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.01.069"},{"key":"2025082709171046000_12.8.e231185.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.11.023"},{"key":"2025082709171046000_12.8.e231185.5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.12659\/AJCR.903327","article-title":"Medication as a Cause of Acute Pancreatitis","volume":"18","author":"Ghatak","year":"2017","journal-title":"Am J Case Rep"},{"key":"2025082709171046000_12.8.e231185.6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.cgh.2017.08.006","article-title":"Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline","volume":"16","author":"Gawron","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025082709171046000_12.8.e231185.7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302779"},{"key":"2025082709171046000_12.8.e231185.8","first-page":"438","article-title":"Eluxadoline (Viberzi): A Mu-Opioid Receptor Agonist for the Treatment Of Irritable Bowel Syndrome With Diarrhea","volume":"42","author":"Maltz","year":"2017","journal-title":"P T"},{"key":"2025082709171046000_12.8.e231185.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnut.2017.00001","article-title":"Sphincter of Oddi Function and Risk Factors for Dysfunction","volume":"4","author":"Afghani","year":"2017","journal-title":"Front Nutr"},{"key":"2025082709171046000_12.8.e231185.10","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/00365520410004776","article-title":"Sphincter of Oddi manometry in patients with acute biliary pancreatitis: evidence for sphincter of Oddi dysfunction in acute biliary pancreatitis","volume":"39","author":"Kruszyna","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"2025082709171046000_12.8.e231185.11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/apt.14504","article-title":"Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder","volume":"47","author":"Harinstein","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025082709171046000_12.8.e231185.12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ajg.2016.542","article-title":"Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea","volume":"112","author":"Cash","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2025082709171046000_12.8.e231185.13","unstructured":"Center for Drug Evaluation and Research. FDA Drug Safety Communication: FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder [Internet]. FDA 2017 https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm546154.htm (accessed 2019 May)."},{"key":"2025082709171046000_12.8.e231185.14","first-page":"90","article-title":"Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report","volume":"89","author":"Chhaparia","year":"2017","journal-title":"Del Med J"},{"key":"2025082709171046000_12.8.e231185.15","first-page":"e3747","article-title":"Eluxadoline-induced Recurrent Pancreatitis in a Young Female without a Gallbladder: A Case Report and Literature Review","volume":"10","author":"Khetpal","year":"2018","journal-title":"Cureus"},{"key":"2025082709171046000_12.8.e231185.16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/gut.41.3.371","article-title":"Influence of cholecystectomy on sphincter of Oddi motility","volume":"41","author":"Luman","year":"1997","journal-title":"Gut"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-231185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:17:21Z","timestamp":1756311441000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-231185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":16,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,28]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bcr-2019-231185"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-231185","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}